RankAlpha logo
Back to Rankings

ZBIO

Zenas BioPharmaB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-17
View Chart
Current thesis
The primary-source set supports a constructive operating setup: obexelimab already showed strong Phase 3 INDIGO efficacy, U.S. and EU filings were framed as on track, SunStone SLE topline is due in Q4 2026, and management said cash runway extends into 2029.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +3.6.
What can break
Any slippage or lack of formal confirmation around the obexelimab FDA filing/acceptance would likely hurt confidence because management had pointed to a Q2 2026 submission timeline. [#SEC-8K-2026-05-13]
Momentum
95
Value
46
Sentiment
44
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $29.00 · Bull $40.00 · Bear $20.00
Data freshness
Prices
As of 2026-07-17
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-17 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-11 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-17
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $42.13
Why
Momentum95 · Δ7d +3.6
Value46 · Δ7d 0.0
Sentiment44 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
95
26% active weight
Current posture
7d trendFlat
Δ7d
+3.6
Δ21d
+61.6
Value
46
39% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
-0.7
Sentiment
44
34% active weight
Current posture
7d trendSoftening
Δ7d
-
Δ21d
-
Why this grade

Composite grade B. Momentum 95.3 / Value 46.4 / Sentiment 43.7

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$1.86B
Beta
-
Shares Out
63.13M
P/E (TTM) · Derived
-3.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-6.63
Rev YoY
-100.0%
EPS YoY
+81.3%
Gross Margin
+99.4%
Op Margin
-
Net Debt
-$263.23M
Current Ratio
11.94
As of 2026-07-17 • Updated nightlySource: Internal modelMethodology